Teijin Pharma to establish new R&D centre to accelerate integrated pharmaceutical development

US$21m centre will be completed by autumn 2015

An impression of the new facility under construction

Teijin Pharma, the core company of the Teijin Group’s medical and pharmaceutical business in Japan, is to build a Technology Integrated Pharmaceutics Centre to support the development of integrated pharmaceuticals, such as the KTF-374 fibrin sheet offering high-performance haemostatic and tissue-sealing properties for surgical operations.

The Centre’s new two-storey building will be equipped with Good Manufacturing Practice zones, manufacturing and testing equipment, and R&D facilities for pharmaceutical/material integration. The 2,300m2 facility will be located in the Pharmaceutical Products Research Laboratories of Teijin’s Iwakuni Factory in western Japan.

Construction begins this month and will be completed in autumn 2015 at a cost of approximately JPY2bn (US$20.8m).

Teijin Group aims to restructure its technology portfolio in the medium to long term by creating a new healthcare business by overlapping the group’s materials and healthcare businesses.

In one such integrative undertaking, Teijin Pharma is developing KTF-374 in collaboration with the Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN).

The Technology Integrated Pharmaceutics Centre will consolidate systems for R&D functions for such integrative products, as well as facilitate the manufacture of investigational drugs and the development of mass production processes for KTF-374.

Companies